We evaluated the response of J76 PRAME TPR expressing CD2::CD28 receptors to primary acute myeloid leukemia (AML) cells that express no CD28 ligands CD80 and CD86 (Figure 4E). This evidence concerns the gene CD86 and acute myeloid leukemia.